{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:02:34Z","timestamp":1790251354374,"version":"4.1.0"},"reference-count":14,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2007,1,19]],"date-time":"2007-01-19T00:00:00Z","timestamp":1169164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2007,2]]},"abstract":"<jats:p><jats:bold>Aim:\u2003<\/jats:bold> In order to clarify the initial step of the mechanism by which bacillus Calmette\u2010Gu\u00e9rin (BCG) exhibits antitumor activity via the immune response induced in the bladder submucosa after intravesical BCG therapy for human bladder cancer, various cytokines secreted in the urine after BCG instillation were measured.<\/jats:p><jats:p><jats:bold>Methods:\u2003<\/jats:bold> After transurethral resection of bladder cancer, a 6\u2010week course of BCG instillation was performed. At the first and sixth weeks' dosings, spontaneously excreted urine was collected before and 4, 8, and 24\u2003h after BCG instillation. The urinary cytokines were determined by Sandwich enzyme\u2010linked immunosorbent assay using monoclonal antibodies against granulocyte\u2013macrophage colony\u2010stimulating factor (GM\u2010CSF), tumor necrosis factor (TNF)\u2010\u03b1, granulocyte colony\u2010stimulating factor (G\u2010CSF), interleukin (IL)\u20101\u03b2, IL\u20108, interferon (IFN)\u2010\u03b3, and IL\u201012.<\/jats:p><jats:p><jats:bold>Results:\u2003<\/jats:bold> After the BCG therapy, various cytokines, such as GM\u2010CSF, TNF\u2010\u03b1, G\u2010CSF, IL\u20101\u03b2, IL\u20108, IFN\u2010\u03b3, and IL\u201012 were secreted, comprising the immune response cascade. The mean urinary excretions of GM\u2010CSF and TNF\u2010\u03b1 4\u2003h after the sixth week's instillation were significantly higher than the pre\u2010instillation levels. There were no significant increases in the urinary IFN\u2010\u03b3 or IL\u201012 levels between 4 and 24\u2003h after the sixth week's instillation. The TNF\u2010\u03b1 level 4\u2003h after the sixth week's instillation had a strong tendency towards the absence of recurrence, with a mean follow\u2010up of 54.1\u2003months. The Kaplan\u2010Meier curve showed the 2, 5, and 10\u2010year recurrence\u2010free survival rates were 72.4%, 65.8%, and 56.4%, respectively.<\/jats:p><jats:p><jats:bold>Conclusions:\u2003<\/jats:bold> We suggested that the urinary levels of TNF\u2010\u03b1 might be essential in antitumor activity after BCG therapy and might play an important role in the prevention of bladder tumor recurrence.<\/jats:p>","DOI":"10.1111\/j.1442-2042.2007.01696.x","type":"journal-article","created":{"date-parts":[[2007,1,19]],"date-time":"2007-01-19T14:21:35Z","timestamp":1169216495000},"page":"140-146","source":"Crossref","is-referenced-by-count":81,"title":["Intravesical instillation therapy with bacillus Calmette\u2010Gu\u00e9rin for superficial bladder cancer: Study of the mechanism of bacillus Calmette\u2010Gu\u00e9rin immunotherapy"],"prefix":"10.1111","volume":"14","author":[{"given":"Yasuyo","family":"Shintani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Inagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Kohjimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunari","family":"Uekado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Shinka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,1,19]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"2785","volume-title":"Campbell's Urology","author":"Malkowicz SB","year":"2002"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)58737-6"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)46972-2"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1989.tb05255.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07422-4"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000073852.24341.4a"},{"key":"e_1_2_5_8_2","first-page":"63","article-title":"[Studies on mechanisms of action of intravesical bacillus Calmette\u2010Gu\u00e9rin immunotherapy in patients with superficial bladder cancers: detection of granulocyte\u2013macrophage colony stimulating factor in urine.]","volume":"15","author":"Sawada Y","year":"1991","journal-title":"Ann. Soc. BCG BRM Immunother."},{"key":"e_1_2_5_9_2","first-page":"187","volume-title":"TNM: Classification of Malignant Tumors","author":"Sobin LH","year":"1997"},{"key":"e_1_2_5_10_2","first-page":"1762","article-title":"Intravesical Bacillus Calmette\u2010Gu\u00e9rin therapy for murine bladder tumors: initiation of the response by fibronectin\u2010mediated attachment of Bacillus Calmette\u2010Gu\u00e9rin","volume":"47","author":"Ratliff TL","year":"1987","journal-title":"Cancer Res."},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02982063"},{"key":"e_1_2_5_12_2","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.4049\/jimmunol.163.8.4246","article-title":"Role of IL\u201012 in the induction and potentiation of IFN\u2010gamma in response to bacillus Calmette\u2010Gu\u00e9rin","volume":"163","author":"O'Donnell MA","year":"1999","journal-title":"J. Immunol."},{"key":"e_1_2_5_13_2","first-page":"698","article-title":"Intravesical bacillus Calmette\u2010Gu\u00e9rin therapy for carcinoma in situ of the bladder and urinary cytokines","volume":"60","author":"Maki Y","year":"1998","journal-title":"Nishinihon J. Urol."},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)64210-1"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00941903"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1442-2042.2007.01696.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1442-2042.2007.01696.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T18:56:24Z","timestamp":1696877784000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1442-2042.2007.01696.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,19]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["10.1111\/j.1442-2042.2007.01696.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1442-2042.2007.01696.x","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,19]]}}}